Literature DB >> 18344117

Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats.

Pierre Sicard1, Stéphanie Delemasure, Claudia Korandji, Anabelle Segueira-Le Grand, Benjamin Lauzier, Jean-Claude Guilland, Laurence Duvillard, Marianne Zeller, Yves Cottin, Catherine Vergely, Luc Rochette.   

Abstract

Among their pleiotropic effects, statins exert antioxidant and anti-inflammatory properties. The aim of this study was to evaluate in normotensive (WKY) and in spontaneously hypertensive rats (SHR) the effect of rosuvastatin (ROSU) treatment on (1) plasma inflammation markers and endogenous NO synthase inhibitor (ADMA) levels, (2) reactive oxygen species (ROS) generated by circulating leukocytes and (3) vascular oxidative stress and tissue inflammation markers. Plasma cytokines were higher in SHR than in WKY, except for IL-4, which was lower in SHR than in WKY. SHR monocytes exhibited higher production of ROS than did WKY monocytes. In the experimental conditions, ROSU did not modify plasma cholesterol levels in SHR but attenuated the increase in systolic blood pressure. In SHR only, ROSU lessened pro-inflammatory cytokines and ADMA levels, increased IL-4 and reduced ROS production in circulating monocytes. These results demonstrate the beneficial effects of ROSU in SHR, independently of any lowering of cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344117     DOI: 10.1080/10715760701885380

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  14 in total

1.  Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models.

Authors:  Mahesh M Ghaisas; Prasad R Dandawate; Suyash A Zawar; Yogesh S Ahire; Santosh P Gandhi
Journal:  Inflammopharmacology       Date:  2010-06-08       Impact factor: 4.473

2.  Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.

Authors:  Sonam Kathuria; Nanjaian Mahadevan; Pitchai Balakumar
Journal:  Mol Cell Biochem       Date:  2012-11-10       Impact factor: 3.396

Review 3.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 4.  Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering.

Authors:  Marios Margaritis; Keith M Channon; Charalambos Antoniades
Journal:  Antioxid Redox Signal       Date:  2014-01-03       Impact factor: 8.401

5.  Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study.

Authors:  Anastazia Kei; Moses Elisaf; Elisavet Moutzouri; Stavroula Tsiara; Evangelos Liberopoulos
Journal:  Int J Hypertens       Date:  2011-05-15       Impact factor: 2.420

6.  Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics.

Authors:  Leonardo Calza
Journal:  Drug Healthc Patient Saf       Date:  2009-08-28

7.  The Arginine/ADMA Ratio Is Related to the Prevention of Atherosclerotic Plaques in Hypercholesterolemic Rabbits When Giving a Combined Therapy with Atorvastatine and Arginine.

Authors:  Saskia J H Brinkmann; Elisabeth A Wörner; Nikki Buijs; Milan Richir; Luc Cynober; Paul A M van Leeuwen; Rémy Couderc
Journal:  Int J Mol Sci       Date:  2015-05-29       Impact factor: 5.923

8.  Atorvastatin represses the angiotensin 2-induced oxidative stress and inflammatory response in dendritic cells via the PI3K/Akt/Nrf 2 pathway.

Authors:  Yuanji Ma; Zhaoyang Chen; Yunzeng Zou; Junbo Ge
Journal:  Oxid Med Cell Longev       Date:  2014-07-03       Impact factor: 6.543

9.  Rosuvastatin attenuates contrast-induced nephropathy through modulation of nitric oxide, inflammatory responses, oxidative stress and apoptosis in diabetic male rats.

Authors:  Jie Deng; Guijun Wu; Chen Yang; Yi Li; Quanmin Jing; Yaling Han
Journal:  J Transl Med       Date:  2015-02-12       Impact factor: 5.531

10.  Current Perspectives on rosuvastatin.

Authors:  Miao Hu; Brian Tomlinson
Journal:  Integr Blood Press Control       Date:  2013-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.